Multiple sclerosis

Fingolimod slows brain atrophy in children with MS

The disease-modifying therapy fingolimod can slow the rate of brain atrophy in children with MS in the same way as it does in adults, an MRI study has shown. A follow up to the PARADIGMS randomised controlled trial involving 215 people aged 10-18 with paediatric-onset multiple sclerosis (PoMS) has shown that fingolimod significantly reduced the ...

Already a member?

Login to keep reading.

© 2021 the limbic